Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863400 | 0.86 | L3MBTL1 (0.58) | MAPTSMN1; SMN2NPC1ALDH1A1HPGD | |
| SCHEMBL16972797 | 0.85 | MAPT (0.50) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL16806634 | 0.84 | GSK3B (0.68) | MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL864323 | 0.84 | MAPT (0.58) | MAPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL6653677 | 0.84 | MAPT (0.49) | MAPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL8481649 | 0.83 | MAPT (0.56) | MAPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL3798190 | 0.82 | CES2 (0.59) | MAPTSMN1; SMN2RAB9ANPC1GAA | |
| SCHEMBL6317361 | 0.82 | NPC1 (0.72) | MAPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL17129733 | 0.82 | L3MBTL1 (0.62) | MAPTSMN1; SMN2RAB9ANPC1KMT2A | |
| SCHEMBL9549256 | 0.82 | KMT2A (0.53) | MAPTSMN1; SMN2RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1431280-A1 | ARYL SULFAMATE DERIVATIVES | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254241-A1 | Enzyme inhibitor; cognition activators | SULT1A1, STS, CYP26A1 | MAPT 3105/4885SMN1; SMN2 3118/4885RAB9A 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.